Price Alert: Shares of Trevi (TRVI) Trade 16.75% Higher at Midday June 23

Equities Staff  |

Shares of Trevi Therapeutics Inc (NASDAQ: TRVI) climbed 16.75% Thursday.

As of 12:12:57 est, Trevi sits at $2.28 and has risen $0.325 per share.

Trevi has moved 13.78% over the last 30 days and has moved YTD 148.02% based on the prior day’s close.

The company is set to release earnings on 2022-08-11.

For technical charts, analysis, and more on Trevi visit the company profile.

About Trevi Therapeutics Inc

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. Trevi is conducting a Phase 2b/3 clinical trial of Haduvio for the treatment of chronic pruritus associated with prurigo nodularis and a Phase 2 trial for chronic cough in patients with idiopathic pulmonary fibrosis (IPF). Trevi is also developing Haduvio for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson's disease and is in the planning stages of a Phase 2 study in this indication. These conditions share a common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems.

To get more information on Trevi Therapeutics Inc and to follow the company's latest updates, you can visit the company's profile page here: Trevi Therapeutics Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

The Best Laid Plans of Mice and Men — Part II
Why I’m Buying the 'New' Value Stocks
Investors Must Understand 5G Wireless Growth Wave: Jeff Kagan
'Goldilocks' Stocks Will Define This Decade



Market Movers

Sponsored Financial Content